Nadofaragene Firadenovec Demonstrates Durable 5-Year Activity in NMIBC : vimarsana.com

Nadofaragene firadenovec led to durable antitumor activity in BCG-unresponsive NMIBC either with CIS or papillary disease, according to 5-year data from the phase 3 Study CS-003.

Related Keywords

United States , American , Vikram Narayan , American Urological Association Annual Meeting , Ferring Pharmaceuticals , Urological Association Annual , Urological Oncology , Grady Memorial Hospital , Emory University School , Winship Cancer , Bacillus Calmette Gu , News , Conference , Urothelial Cancer ,